Market Overview

Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

Amarin Corporation plc (NASDQ: AMRN) announced today that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study of Vascepa┬« (icosapent ethyl) capsules has surpassed 6,000.   

The REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) study is a multinational, prospective, randomized, double-blind, placebo-controlled, parallel-group study taking place at over 400 clinical sites in 11 countries to evaluate the effectiveness and safety of Vascepa┬« (icosapent ethyl) capsules, as an adjunct to optimized statin therapy, in reducing the incidence of first major cardiovascular events in a patient population at high risk for such events. The control arm of the study consists of patients on optimized statin therapy plus placebo. The active arm of the study consists of patients on optimized statin therapy plus Vascepa 4g/day. The high-risk patient population in REDUCE-IT has both a mean and median baseline triglyceride (TG) level over 200 mg/dL, a level substantially above those from recently conducted outcomes trials of other prescription lipid modifying therapies. Furthermore, Amarin has taken steps to ensure that the final baseline TG levels remain above 200

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters